Therapeutic studies investigating the efficacy of LAG3 inhibition in EAC will also provide predictive evidence on the determination of the LAG3 expression in the tumour microenvironment, as we have learned in the past for the determination of PD-L1 in lung cancer. This evidence concerns the gene CD274 and neoplasm.